Why the study?
Arrhythmic sudden cardiac death is a major cause of death, but risk stratification remains challenging because conflicting results have limited the clinical use of previously tested biomarkers.
Can plasma and genetic biomarkers predict ventricular arrhythmias and sudden cardiac death in patients without coronary artery disease?
Can plasma and genetic biomarkers predict ventricular arrhythmias and sudden cardiac death in patients without coronary artery disease?
This review highlights the emerging role of novel plasma and genetic biomarkers for sudden cardiac death risk stratification in patients without coronary artery disease.
Conflicting biomarker results limit SCD risk stratification in practice; leaves open microRNA utility pending prospective validation.
Arrhythmic sudden cardiac death (SCD) represents a major worldwide public health problem accounting for 15-20% of deaths. Risk stratification to identify patients at risk of SCD is crucial in order to implement preventive measures in the general population. Several biomarkers have been tested exploring different pathophysiological mechanisms of cardiac conditions. Conflicting results have been described limiting so far their use in clinical practice. The use of new biomarkers such as microRNAs and sex hormones and the emerging role of genetic on risk prediction of SCD is a current research topic showing promising results.This review outlines the role of plasma biomarkers to predict ventricular arrhythmias and SCD in non coronary artery disease with a special focus on their relationship with the genetic biomarkers.
No takes yet. Share an insight, caveat, or question.
Balla et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: